By The RX Index Editorial Team · · FDA labels, manufacturer pricing, and Medicare Bridge confirmed
Comparison Guide · April 2026
Wegovy Pill vs Foundayo Pill: Which Oral GLP-1 Wins in 2026?
The short answer (before you scroll)
In Wegovy pill vs Foundayo pill, the trial data favors Wegovy pill. The daily routine favors Foundayo. That's the real tradeoff — and it's the one almost no other comparison puts in a single sentence.
Wegovy pill (oral semaglutide)
FDA-approved December 22, 2025. Average 16.6% weight loss at 64 weeks (people who stayed on treatment). FDA label includes reducing major adverse cardiovascular events in adults with established heart disease.
Foundayo (orforglipron)
FDA-approved April 1, 2026. Average 12.4% weight loss at 72 weeks (people who stayed on treatment, top dose). Taken any time, with or without food — no 30-minute morning window.
Both start at $149/month self-pay. Eligible commercially insured patients may pay as little as $25/month. Starting July 1, 2026, eligible Medicare Part D beneficiaries can access all formulations of both pills through the new Medicare GLP-1 Bridge at a $50/month copay. One catch nobody tells you: Foundayo's highest doses jump from $299 to $349/month if you miss Lilly's 45-day refill window.
The one-sentence pick:
Pick Wegovy pill if you want the stronger trial number, you have heart disease, or you can commit to a structured morning. Pick Foundayo if your mornings are chaotic, you need coffee early, or you're managing other morning meds.
Ro carries both pills and runs a free insurance check that includes the new Medicare Bridge pathway.
Primary sources verified April 23, 2026:
At a glance: Wegovy pill vs Foundayo pill
Every row below is pulled from the current FDA labels or live manufacturer and provider pages, verified .
| Feature | Wegovy Pill (semaglutide) | Foundayo (orforglipron) |
|---|---|---|
| Maker | Novo Nordisk | Eli Lilly |
| FDA approval date | December 22, 2025 | April 1, 2026 |
| Drug class | Peptide GLP-1 receptor agonist | Small-molecule, non-peptide GLP-1 receptor agonist |
| How often | Once daily | Once daily |
| Timing rules | Empty stomach, first thing in the morning, ≤4 oz water, 30-min wait before food, drinks, or other oral meds | Any time of day, with or without food, no water restriction |
| Approved doses | 1.5 mg, 4 mg, 9 mg, 25 mg | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg |
| Avg weight loss (all participants, top dose) | 13.6% at 64 weeks | 11.1% at 72 weeks |
| Avg weight loss (people who stayed on treatment) | 16.6% | 12.4% |
| ≥20% weight loss (stayed on treatment, top dose) | 27.9% | 18.4% |
| Cardiovascular risk indication | Yes — reduces major adverse CV events in adults with established CVD | No |
| Notable drug interactions | Slows gastric emptying; may affect absorption of other oral meds | CYP3A4 substrate; simvastatin dose cap; OC backup required |
| Boxed warning | Thyroid C-cell tumors (MTC) | Thyroid C-cell tumors (MTC) |
| Cash price (starter dose, Ro) | $149/month | $149/month (0.8 mg) |
| Cash price (top dose, Ro) | $299/month | $299/month with 45-day refill; $349/month without |
| With commercial insurance savings card | As low as $25/month (eligibility required) | As low as $25/month (eligibility required) |
| Medicare Part D (weight loss) | $50/month via Medicare GLP-1 Bridge starting July 1, 2026 | $50/month via Medicare GLP-1 Bridge starting July 1, 2026 |
| Best fit | Structured mornings, strongest obesity-trial number, heart disease, OC users | Chaotic mornings, needs coffee early, multiple morning meds, needs dose granularity |
Which actually produces more weight loss: Wegovy pill or Foundayo?
Wegovy pill's highest approved dose (25 mg) produced 16.6% average weight loss at 64 weeks among patients who stayed on treatment in the OASIS 4 trial, versus 12.4% for Foundayo's highest dose (17.2 mg) at 72 weeks among patients who stayed on treatment in the ATTAIN-1 trial. That's roughly a 3-percentage-point advantage for Wegovy pill. But these are separate trials with different populations and durations — not a direct head-to-head.
Wegovy pill trial results (OASIS 4)
OASIS 4 enrolled 307 adults without diabetes with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Randomized 2:1 to once-daily 25 mg oral semaglutide or placebo for 64 weeks, alongside lifestyle counseling.
| Outcome | Wegovy pill 25 mg | Placebo |
|---|---|---|
| Avg weight change (all participants) | −13.6% | −2.4% |
| Avg weight change (people who stayed on treatment) | −16.6% | −2.7% |
| ≥5% weight loss | 76.3% | 31.3% |
| ≥10% weight loss | 59.8% | — |
| ≥15% weight loss | 47.0% | — |
| ≥20% weight loss | 27.9% | 2.9% |
Serious adverse events were actually less frequent on oral semaglutide than placebo (3.9% vs 8.8%). Source: Wegovy prescribing information
Foundayo trial results (ATTAIN-1)
| Outcome | Foundayo 17.2 mg | Placebo |
|---|---|---|
| Avg weight change (all participants) | −11.1% | −2.1% |
| Avg weight change (people who stayed on treatment) | −12.4% | — |
| Avg pounds lost (top dose, stayed on treatment) | 27.3 lbs | 2.2 lbs |
| ≥5% weight loss | 71.5% | — |
| ≥10% weight loss | 54.5% | — |
| ≥15% weight loss | 35.9% | — |
| ≥20% weight loss | 18.4% | — |
Foundayo's label lists hair loss as a common adverse reaction at the top dose, alongside classically GLP-1 GI effects. Source: Foundayo prescribing information
The Novo Nordisk “ORION” indirect comparison
On April 2, 2026 — one day after Foundayo's approval — Novo Nordisk announced a population-adjusted indirect comparison showing oral semaglutide with roughly a 3-percentage-point weight-loss advantage over orforglipron and ~4× lower odds of stopping due to side effects.
- ⚠It's not a head-to-head randomized trial.
- ⚠It was funded and presented by the maker of one of the two drugs.
- ⚠Eli Lilly disputes the methodology.
- ⚠The Novo analysis used a 36 mg orforglipron dose tested in phase 3, not the 17.2 mg dose the FDA actually approved.
The one head-to-head trial (ACHIEVE-3) — and why it doesn't settle this
The only randomized head-to-head between orforglipron and oral semaglutide published to date is ACHIEVE-3, in The Lancet (February 2026). It showed Foundayo superior to oral semaglutide on HbA1c reduction. But ACHIEVE-3 studied type 2 diabetes, used oral semaglutide at 7 mg and 14 mg (the Rybelsus diabetes doses — not the 25 mg Wegovy pill obesity dose), and its primary endpoint was HbA1c, not weight loss. For the question this page answers — which pill wins for weight loss in adults without diabetes — it's not decisive.
Honest read of the efficacy question
The numbers favor Wegovy pill. They don't close the case. Foundayo's 17.2 mg approved dose may not be its ceiling. The 3-percentage-point gap in trial averages also matters less than most people think once real-world adherence enters the picture. People who can't stick with Wegovy pill's morning fasting window often just stop taking it. Weight loss that never starts is zero percent. If raw efficacy is the only thing that matters, Wegovy pill is the safer bet today. If you know yourself well enough to admit that a 30-minute morning fasting window will wreck your adherence by week four, Foundayo is a fully legitimate choice.
Starts at $149/month cash · as low as $25/month with eligible commercial insurance · $50/month under the Medicare Bridge starting July 1, 2026
Daily routine reality: the 30-minute rule vs. take-anytime
Wegovy pill — the 30-minute rule
Must be taken first thing in the morning on an empty stomach with no more than 4 oz of plain water, followed by at least a 30-minute wait before food, other drinks, or any other oral medication.
Foundayo — take anytime
Swallow the tablet whole, any time of day, with or without food, any amount of water. No fasting, no waiting, no timing constraint. This is the approved FDA label language — not marketing.
Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist. Most other GLP-1s, including semaglutide, are peptides. Its approved administration does not require the fasting protocol that oral semaglutide needs to be absorbed reliably. That structural difference is why the label allows any-time dosing with or without food.
Community voice (not medical evidence)
“Problem is I need coffee immediately in the morning.”— r/WegovyPillWeightLoss, “When do you drink your coffee?”
“Do not drink coffee until 30 minutes after the pill.”— Same thread
“Wait so there's finally a weight loss pill instead of the Wegovy pill?”— r/FoundayoUS
Who should take the 30-minute rule seriously
If any of these are true, the 30-minute window will probably hurt your adherence:
- ⚠You take levothyroxine / Synthroid (which also needs an empty stomach; the two drugs compete for the same morning window)
- ⚠You exercise within 30 minutes of waking
- ⚠You're a parent managing school or daycare mornings
- ⚠You work night shifts or rotating shifts
- ⚠You travel frequently across time zones
- ⚠You wake up needing coffee, water, or medication immediately
In those cases, Foundayo is likely the better real-world fit — even if Wegovy pill has the slightly stronger trial number.
Wegovy pill vs Foundayo pill cost: the full price grid, verified April 2026
Both start at $149/month for the lowest self-pay dose. At maintenance doses, Wegovy pill tops out at $299/month. Foundayo's highest two doses are $299/month if you refill within 45 days and $349/month otherwise.
| Dose | LillyDirect / NovoCare (manufacturer direct) | Ro (matches manufacturer pricing) |
|---|---|---|
| Foundayo 0.8 mg | $149/month | $149/month |
| Foundayo 2.5 mg | $199/month | $199/month |
| Foundayo 5.5 mg | $299/month | $299/month |
| Foundayo 9 mg | $299/month | $299/month |
| Foundayo 14.5 mg | $299/month (45-day refill) / $349/month without | Same as LillyDirect |
| Foundayo 17.2 mg | $299/month (45-day refill) / $349/month without | Same as LillyDirect |
| Wegovy pill 1.5 mg | $149/month | $149/month |
| Wegovy pill 4 mg | $149/month (promo through Aug 31, 2026, then $199) | Same as NovoCare |
| Wegovy pill 9 mg | $299/month | $299/month |
| Wegovy pill 25 mg | $299/month | $299/month |
The price-cliff fine print competitors leave out
| Fine-print issue | How most pages summarize it | What the manufacturer actually says |
|---|---|---|
| Wegovy pill 4 mg (mid-titration) | “Starts at $149, then $199–$299” | NovoCare: $149 for 1.5 mg and 4 mg — but the 4 mg price is a promo that ends August 31, 2026, then reverts to $199 |
| Foundayo 14.5 mg / 17.2 mg | “Tops out at $299” | Lilly's self-pay list price for these doses is $349/month. The $299 price requires refilling within 45 days of your previous delivery. |
Does insurance cover Wegovy pill or Foundayo?
Eligible commercially insured patients may pay as little as $25/month through the manufacturer savings cards on either pill. Coverage itself is plan-specific, and prior authorization is common.
Commercial insurance
- ○Wegovy pill: Eligible commercially insured patients pay as little as $25/month with the Novo Nordisk Wegovy Savings Offer (maximum $100 off a 1-month, $200 off 2-month, $300 off 3-month prescription). If your plan doesn't cover the drug, the Savings Offer caps out-of-pocket at $149/month for 1.5 mg and 4 mg, and $299/month for 9 mg and 25 mg.
- ○Foundayo: Eligible commercially insured patients pay as little as $25/month with the Lilly Foundayo Savings Card (card expires December 31, 2026; terms may change). Government beneficiaries are excluded from both programs.
Prior authorization
Expect one. Both are newer brand-name medications on most commercial plans, and both typically require insurance pre-approval. Ro's insurance concierge handles the paperwork for either drug — that's a practical reason to start there if you're planning to use insurance.
Medicare coverage just changed — here's what actually happens July 1, 2026
Starting July 1, 2026: eligible Medicare Part D beneficiaries access both Wegovy pill and Foundayo for weight management at a $50/month copay through the new Medicare GLP-1 Bridge.
Key details directly from CMS:
- ·Who's eligible: Medicare beneficiaries enrolled in a standalone Part D plan (PDP) or Medicare Advantage with drug coverage (MA-PD), plus certain other eligible plan types.
- ·Clinical criteria: BMI of 35+ on its own, OR BMI 27+ with at least one qualifying clinical criterion. Provider must submit prior authorization.
- ·Price: $50/month copay, flat regardless of dose or product.
- ·How it works: Runs outside normal Part D via a single central processor (Humana/LI NET).
- ·Program duration: Extended through December 31, 2027 per CMS's April 21, 2026 announcement.
- ·What's covered: All formulations of Wegovy (pill and injection) and all formulations of Foundayo. Zepbound KwikPen is also covered; other Zepbound formulations, Ozempic, Mounjaro, Rybelsus, and Saxenda are not.
- ·Important wrinkle: If your provider prescribes Wegovy for its cardiovascular indication (not weight loss), that runs through standard Part D, not the Bridge.
Ro's insurance checker now includes the Medicare Bridge pathway in its personalized report.
HSA and FSA
HSA/FSA eligibility for GLP-1 medications prescribed for weight management varies by plan. Confirm with your plan administrator before assuming coverage.
Side effects and interaction issues that matter before you choose
Side effects both pills share
Reported in ≥5% of trial patients on either drug:
Foundayo's label also lists hair loss, GERD, flatulence, eructation, and abdominal distension as common adverse reactions at the top dose. Both drugs carry the same boxed warning for thyroid C-cell tumors (MTC) based on rodent studies.
Interactions that actually change the decision
Foundayo and oral contraceptives
Foundayo can reduce the effectiveness of oral birth control pills. Lilly's labeling recommends a non-oral backup method for 30 days after starting Foundayo and for 30 days after each dose increase. If your only birth control method is an oral pill and switching to a backup for weeks isn't workable, Wegovy pill is the cleaner pick on this single variable.
Foundayo and strong CYP3A4 inhibitors
Foundayo is metabolized through the CYP3A4 enzyme. When used with a strong CYP3A4 inhibitor (clarithromycin, itraconazole, ritonavir, and others), the Foundayo dose shouldn't exceed 9 mg daily — locking you out of the strongest approved doses.
Foundayo and simvastatin
The simvastatin dose should not exceed 20 mg daily while on Foundayo due to pharmacokinetic interaction.
Both pills delay gastric emptying
Both can affect how your body absorbs other oral medications. Your clinician or pharmacist should review your full medication list before you start either drug.
Who should not take either pill
Do not take Wegovy pill or Foundayo if you have:
- ✕Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- ✕Prior serious hypersensitivity reaction to semaglutide (Wegovy pill) or orforglipron (Foundayo), or to inactive ingredients in either product
- ✕Pregnancy — both manufacturers advise discontinuation at least 2 months before a planned pregnancy
- ✕Current use of another GLP-1 receptor agonist (Wegovy injection, Ozempic, Mounjaro, Zepbound, Saxenda, Rybelsus)
- ✕Pediatric use — neither pill is FDA-approved for patients under 18
History of pancreatitis or active gallbladder disease should be discussed with a clinician before starting either drug.
Which pill wins for your specific situation
Both pills are legitimate. The winner for you isn't the winner in the average trial.
| If you… | Our editorial pick | Why |
|---|---|---|
| Want the strongest trial-backed weight loss | Wegovy pill | 16.6% vs 12.4% at top doses among people who stayed on treatment |
| Have established cardiovascular disease | Wegovy pill | FDA-indicated to reduce major adverse CV events; Foundayo is not |
| Need coffee, breakfast, or other meds within 30 min of waking | Foundayo | No fasting window, no water rule, any time of day |
| Travel frequently or have irregular schedules | Foundayo | Flexible timing vs strict morning window |
| Use oral contraceptives only (no backup method) | Wegovy pill | Avoids Foundayo's 30-day backup contraception requirement |
| Take simvastatin above 20 mg | Wegovy pill | Foundayo caps simvastatin at 20 mg |
| Are on a strong CYP3A4 inhibitor | Wegovy pill | Foundayo limits you to 9 mg max in this case |
| Are already on Wegovy injection and want to try a pill | Wegovy pill | Direct switch per Novo guidance: stop injection, start 25 mg pill one week later |
| Need fine-grained dose titration | Foundayo | Six dose strengths vs four for Wegovy pill |
| Are on Medicare qualifying for the Bridge | Either | Both pills are $50/month under the Medicare GLP-1 Bridge starting July 1, 2026 |
| Want an insurance concierge handling prior auth | Either — go through Ro | Ro's concierge supports both medications |
Does Wegovy pill have a heart-health advantage?
Yes — this is the single clearest tiebreaker for readers with heart disease. Wegovy (both pill and injection) is FDA-approved to reduce the risk of major adverse cardiovascular events — cardiovascular death, heart attack, and stroke — in adults with established cardiovascular disease plus obesity or overweight. Foundayo currently has no cardiovascular indication.
- ○If you have known CVD, this is a concrete, FDA-approved reason to prefer Wegovy pill. Semaglutide was studied in the 17,600-patient SELECT trial, which demonstrated the cardiovascular benefit that earned Wegovy its indication. Orforglipron has no equivalent trial yet.
- ○If you don't have diagnosed CVD, the indication is less decisive — but some clinicians treat it as a tiebreaker in Wegovy pill's favor, on the logic that a medication with proven cardiovascular benefit carries less long-term uncertainty than one without.
Is there a direct head-to-head trial between Wegovy pill and Foundayo?
Not for the obesity-approved doses most readers care about. Here's the evidence hierarchy as it stands today:
- Direct obesity head-to-head at approved doses: does not exist.
- Direct head-to-head in type 2 diabetes at Rybelsus doses (ACHIEVE-3): favors Foundayo on HbA1c reduction. Doesn't answer the obesity question at Wegovy pill's 25 mg dose.
- Indirect obesity comparison (ORION, Novo-funded): favors Wegovy pill on weight loss and side-effect discontinuation. Disputed by Lilly. Not a randomized trial.
- Separate trial results (OASIS 4 vs ATTAIN-1): favors Wegovy pill by ~3 percentage points on average weight loss. Not directly comparable.
Switching between Wegovy injection, Wegovy pill, and Foundayo
Wegovy injection → Wegovy pill (25 mg daily)
Per Wegovy's prescribing information: stop the injection, then begin the 25 mg daily pill one week after your last injection. Same active ingredient, different delivery form — the simplest of the three switch options.
Wegovy pill (25 mg daily) → Wegovy injection (2.4 mg weekly)
Per Wegovy's prescribing information: you can start the weekly injection the day after your last pill dose.
Wegovy ↔ Foundayo (or across other GLP-1 classes)
Foundayo should not be used concurrently with another GLP-1 receptor agonist. Any cross-molecule switching plan should be directed by your prescriber. There's no universal “washout” instruction in either label; your clinician will design the timing based on your specific situation.
Switching from tirzepatide (Zepbound or Mounjaro)
Tirzepatide is a different molecule — a dual GIP/GLP-1 agonist. Both oral options produce less weight loss than tirzepatide at top doses. If you're already on Zepbound or Mounjaro and losing weight well, there's usually no clinical reason to switch purely for the pill format. Your prescriber is the right place to raise the question.
Where to actually get Wegovy pill and Foundayo right now
Both pills are available now through multiple channels. For most readers comparing both drugs side by side, Ro is the best first click — it carries both medications, matches manufacturer cash pricing, includes a free insurance checker that covers the new Medicare Bridge pathway, and handles prior authorization paperwork.
Primary recommendation
Ro
- ✓Carries both Wegovy pill and Foundayo plus a comprehensive GLP-1 formulary
- ✓Free GLP-1 Insurance Coverage Checker — includes the new Medicare Bridge pathway
- ✓Insurance concierge that handles prior-authorization paperwork for either drug
- ✓Switch between pill and injection, or between Wegovy and Zepbound, on the same platform
- ✓Ro Body membership: $39 first month, then $149/month ongoing — or as low as $74/month annual prepay
- ✓Medication cost is separate and matches LillyDirect and NovoCare pricing exactly
Honest disclosure: Ro does not include medication cost inside the Ro Body membership — medication is billed separately at the self-pay or insurance price. The membership buys you the prescriber, insurance concierge, and refill management. If zero-membership direct checkout is your top priority, LillyDirect or NovoCare are simpler.
→ Check your eligibility for Wegovy pill or Foundayo on RoSecondary option
Sesame Care
Works well if you want provider choice or Costco-member pricing. Carries Wegovy pill, Wegovy pen, Ozempic, Mounjaro, Foundayo, Zepbound, and Saxenda. Subscription pricing starts at $59/month. No insurance required to use the program.
→ Compare brand-name options on Sesame CareManufacturer direct
LillyDirect (Foundayo)
Same pricing as Ro. No telehealth — you need a prescription from your own clinician. Pharmacy sends to your door or Walmart pickup where available.
NovoCare (Wegovy pill)
Same pricing as Ro. No telehealth — you need a prescription from your own clinician. Amazon Pharmacy available for faster delivery.
What patients are saying
Testimonials for both pills are still early — Wegovy pill launched broadly in January 2026 and Foundayo in April. These are real, attributable public quotes about the service experience, not medical efficacy. Individual outcomes vary.
“My provider was very knowledgeable about GLP-1s and the different options for weight loss. She answered my questions thoroughly and was very efficient and on top of things.”
— Patient testimonial published on Sesame Care's weight loss program page
“Refills and delivery have been hassle-free. My medicine arrived on time, at my door.”
— NovoCare Pharmacy patient testimonial (Novo states all testimonials on novocare.com are from patients using NovoCare Pharmacy)
How we verified this page
What we actually verified (as of ):
- ✓Wegovy pill dosing instructions — confirmed from the official FDA-approved prescribing information
- ✓Wegovy pill cardiovascular indication — confirmed from the same label's Indications and Usage section
- ✓Foundayo dosing instructions — confirmed from the official FDA-approved prescribing information
- ✓Foundayo oral contraceptive, CYP3A4, and simvastatin guidance — confirmed from the same label's Drug Interactions section
- ✓OASIS 4 trial results (Wegovy pill, 13.6% / 16.6% weight loss) — confirmed from Wegovy prescribing information
- ✓ATTAIN-1 trial results (Foundayo, 11.1% / 12.4% weight loss) — confirmed from Foundayo prescribing information
- ✓LillyDirect Foundayo pricing across all 6 doses, including the 45-day refill condition — confirmed from foundayo.lilly.com/coverage-savings
- ✓NovoCare Wegovy pill pricing across all 4 doses, including the 4 mg promo expiration date of August 31, 2026 — confirmed from novocare.com/pharmacy/wegovy.html
- ✓Ro cash pricing matching manufacturer pricing, plus membership terms — confirmed from ro.co/weight-loss/pricing
- ✓Sesame Care availability of both drugs — confirmed from sesamecare.com
- ✓Medicare GLP-1 Bridge details ($50/month copay, July 1, 2026 launch, extended through December 31, 2027) — confirmed from CMS.gov Medicare GLP-1 Bridge page
- ✓ACHIEVE-3 trial scope (type 2 diabetes, Rybelsus doses, not Wegovy pill 25 mg) — confirmed from The Lancet February 2026 publication
Wegovy pill vs Foundayo pill: FAQ
Is Wegovy pill stronger than Foundayo?+
On the current trial evidence at approved doses, yes — Wegovy pill produced about 3 percentage points more average weight loss (16.6% vs 12.4% among people who stayed on treatment at top doses). But these are separate trials with different populations, not a direct head-to-head. The evidence favors Wegovy pill; it doesn't close the case.
Is Foundayo easier to take than Wegovy pill?+
Yes — this is Foundayo's clearest advantage. Wegovy tablets require an empty stomach, up to 4 oz of water, and a 30-minute wait before food or other oral medications. Foundayo can be taken any time of day, with or without food, with no water restriction.
Can I drink coffee after taking the Wegovy pill?+
Not within 30 minutes. Wegovy pill's label requires a 30-minute wait after taking the tablet before eating, drinking anything other than the small amount of water used to swallow the pill, or taking other oral medications. Foundayo has no such restriction.
Does Foundayo affect birth control?+
Yes. Foundayo can reduce the effectiveness of oral contraceptive pills. Lilly's label recommends using a backup non-oral method of contraception for 30 days after starting Foundayo and for 30 days after each dose increase. Wegovy pill's label does not include this specific warning.
Which one is cheaper without insurance?+
They start at the same price — $149/month for the lowest dose of each. At maintenance doses, Wegovy pill stays at $299/month. Foundayo's highest doses (14.5 mg and 17.2 mg) are $299/month only if you refill within 45 days; otherwise they're $349/month.
Does Medicare cover Wegovy pill or Foundayo for weight loss?+
Starting July 1, 2026, eligible Medicare Part D beneficiaries can access all formulations of both Wegovy and Foundayo for weight management through the new Medicare GLP-1 Bridge, at a $50/month copay. Eligibility requires enrollment in a qualifying Part D or MA-PD plan, a BMI of 35+ (or 27+ with qualifying clinical criteria), and a prior authorization submitted to the CMS central processor. The Bridge program has been extended through December 31, 2027.
Is there a direct Wegovy pill vs Foundayo trial?+
Not for obesity. The one head-to-head trial (ACHIEVE-3, The Lancet February 2026) studied type 2 diabetes and used lower oral semaglutide doses (7 mg and 14 mg) — not the 25 mg Wegovy pill obesity dose.
Can I switch from injectable Wegovy to Wegovy pill?+
Yes. Per Wegovy's prescribing information, stop the weekly injection and begin the 25 mg daily pill one week after your last injection.
Which provider is best for FDA-approved oral GLP-1s?+
For comparing both pills in one place with insurance support, Ro is the strongest first click — it carries both Wegovy pill and Foundayo at manufacturer-matched pricing, offers a free insurance checker that now includes the Medicare Bridge pathway, and handles prior auth paperwork. Sesame Care is a strong secondary if you want provider choice.
What happens if I miss Lilly's 45-day Foundayo refill window?+
The self-pay price on the 14.5 mg and 17.2 mg doses goes up from $299 to $349/month. Lower doses ($149 for 0.8 mg, $199 for 2.5 mg, $299 for 5.5 mg and 9 mg) are not subject to the 45-day condition.
Does Ro charge a membership fee on top of the medication?+
Yes. Ro Body membership is $39 your first month, then $149/month ongoing, or as low as $74/month if you prepay on an annual plan. Medication cost is separate and matches manufacturer pricing.
Are either of these pills better for people with heart disease?+
Wegovy (both pill and injection) is FDA-approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight. Foundayo currently has no cardiovascular indication. For patients with known CVD, this is a concrete reason to prefer Wegovy pill.
Still not sure which oral GLP-1 is right for you?
Ro carries both Wegovy pill and Foundayo, includes a free insurance check that now covers the Medicare Bridge pathway, and handles prior authorization. No obligation to check.
Related guides
About this page
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. We verify prices monthly directly from manufacturers and telehealth platforms. We disclose affiliate relationships: we may earn a commission when readers start treatment through linked providers (Ro, Sesame Care), at no extra cost to the reader. Editorial recommendations are made independently based on the evidence above, not commission structure.
This page is not medical advice and is not a substitute for a consultation with a licensed clinician. Foundayo and Wegovy are registered trademarks of their respective manufacturers. Both medications carry boxed warnings and should only be used under clinical supervision.
Update cadence: Pricing and program terms re-verified monthly. Quarterly full-review audits for FDA label changes, new trial data, and insurance formulary changes.
Affiliate disclosure: Links to Ro and Sesame Care on this page use our affiliate tracking utility and carry rel="nofollow sponsored noopener". The RX Index may earn a commission when readers start treatment through those links, at no extra cost to you. LillyDirect and NovoCare links are plain external links with no affiliate compensation to us.